Search results
Dementia Action Week 2024: the future of Alzheimer’s diagnostics
Pharmaceutical Technology via Yahoo Finance· 4 days agoNew methods to measure tau and other biomarkers are in development. Several companies are developing...
This is why SC state lawmakers like me voted to ban transgender health care for children
The State via Yahoo News· 20 hours agoFurther review of the Standards offers no comfort. The Standards indicates there is only limited...
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
Morningstar· 1 day agoEnrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025Company committed to addressing the most aggressive type of brain ...
Scripps Research Front Row Lecture
KPBS San Diego· 2 days agoAll proteins have a correct way of “folding” themselves into their three-dimensional structures. When this folding process goes awry, including processes...
In-depth coverage of a hidden danger in baby food: Toxic Inaction leaves kids at risk
WJLA· 17 hours agoHundreds of families across the US are dealing with children who were poisoned by lead hiding in...
As Europe pumps breaks on transgender care for minors, US pushes full steam ahead
WJLA· 3 days agoThere’s a shift underway in Europe to restrict medical gender-affirming care for children and teens....
Lisa Jarvis: Would you get tested for an Alzheimer’s gene?
Tulsa World· 4 days agoThe finding comes with caveats, but still has near-term implications for studying, diagnosing and...
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA)...
WTRF Wheeling· 24 hours agoMoleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat ...
Treatment-resistant depression linked to body mass index: Study
Medical Xpress· 2 days agoThe report, published May 15 in The American Journal of Psychiatry, provides insights into the...
ABMRF Invests in Amygdala Neurosciences to Develop ANS-858 for Alcohol Use Disorder
The Yuma Sun· 3 days agoANS-858 is a new selective, reversible, orally bioavailable ALDH2 Inhibitor in pre-clinical development to reduce craving. BEL AIR, Md. and SAN FRANCISCO, May 14, 2024 /PRNewswire ...
